MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/04/6502-437-442$20.00
Mol Pharmacol 65:437-442, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beagles, K.
Right arrow Articles by Bayer, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beagles, K.
Right arrow Articles by Bayer, B.

Systemic Morphine Administration Suppresses Genes Involved in Antigen Presentation

Karen Beagles, Anton Wellstein, and Barbara Bayer

Departments of Pharmacology (K.B.), Oncology (A.W.), and Neuroscience (B.B.), Georgetown University, Washington, DC

Administration of opioids in both humans and animal models results in significant alterations in immune system responsiveness. Although the majority of studies have focused on phenotypic changes in immune cells after short- and long-term morphine administration, few studies have determined whether alterations in gene expression profiles accompany these effects. To address this question, rats were treated with either morphine (20 mg/kg) or saline, and changes in gene expression and function in blood leukocytes were examined. Within 2 h, morphine administration resulted in a decrease in blood leukocyte expression of the major histocompatibility complex class II (MHC II RT1.B {beta}) (–3.27-fold) and related molecules, including the MHC II invariant chain (–2.73-fold). Furthermore, these changes in gene expression were accompanied by a significant decrease in surface MHC II RT1.B {beta} protein expression, specifically on B lymphocytes. Morphine administration was also found to inhibit IL-4 induced up-regulation of MHC II RT1.B {beta} cell surface expression on B lymphocytes. This is the first demonstration that receptors involved in antigen presentation are modified after systemic morphine administration. We propose that the inability of B lymphocytes to up-regulate key immune proteins, such as the MHC II molecule, after exposure to antigen-induced cytokine production may account for the increase in the susceptibility to bacterial and viral infections such as HIV in both drug abusers and patients receiving morphine.


Received June 27, 2003; accepted November 7, 2003

Address correspondence to: Dr. Barbara Bayer, Georgetown University, Department of Neuroscience, 3970 Reservoir Rd NW, New Research Building Room EG17C, Washington, DC 20057. E-mail: bayerb{at}georgetown.edu




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
I. Tegeder and G. Geisslinger
Opioids As Modulators of Cell Death and Survival--Unraveling Mechanisms and Revealing New Indications
Pharmacol. Rev., September 1, 2004; 56(3): 351 - 369.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics